Cargando…

Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients

BACKGROUND: The relationship between blood pressure (BP) control and the risk of new-onset hyperuricemia remains uncertain. We aimed to examine the association between degree of time-averaged on-treatment BP control and new-onset hyperuricemia in general hypertensive patients. METHODS: A total of 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qinqin, Zhang, Yuanyuan, Cao, Jingjing, Zhang, Jingping, Nie, Jing, Liang, Min, Li, Jianping, Zhang, Yan, Wang, Binyan, Huo, Yong, Wang, Xiaobin, Hou, Fan Fan, Xu, Xiping, Qin, Xianhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723605/
https://www.ncbi.nlm.nih.gov/pubmed/33313179
http://dx.doi.org/10.21037/atm-20-3017
_version_ 1783620375864672256
author Li, Qinqin
Zhang, Yuanyuan
Cao, Jingjing
Zhang, Jingping
Nie, Jing
Liang, Min
Li, Jianping
Zhang, Yan
Wang, Binyan
Huo, Yong
Wang, Xiaobin
Hou, Fan Fan
Xu, Xiping
Qin, Xianhui
author_facet Li, Qinqin
Zhang, Yuanyuan
Cao, Jingjing
Zhang, Jingping
Nie, Jing
Liang, Min
Li, Jianping
Zhang, Yan
Wang, Binyan
Huo, Yong
Wang, Xiaobin
Hou, Fan Fan
Xu, Xiping
Qin, Xianhui
author_sort Li, Qinqin
collection PubMed
description BACKGROUND: The relationship between blood pressure (BP) control and the risk of new-onset hyperuricemia remains uncertain. We aimed to examine the association between degree of time-averaged on-treatment BP control and new-onset hyperuricemia in general hypertensive patients. METHODS: A total of 10,617 hypertensive patients with normal uric acid (UA) concentrations (<357 µmol/L) at baseline were included from the UA Sub-study of the China Stroke Primary Prevention Trial (CSPPT). Participants were randomized to receive a double-blind daily treatment of enalapril 10 mg and folic acid 0.8 mg or enalapril 10 mg alone. BP measurements were taken every three months after randomization. The primary outcome was new-onset hyperuricemia, defined as a UA concentration ≥417 µmol/L in men or ≥357 µmol/L in women at the exit visit. RESULTS: Over a median of 4.4 years, 1,664 (15.7%) participants developed new-onset hyperuricemia. Overall, there was a significantly positive association between time-averaged on-treatment diastolic BP (DBP) and new-onset hyperuricemia (per 10 mmHg increment; OR 1.13; 95% CI: 1.02–1.26). Consistently, a significantly higher risk of new-onset hyperuricemia was found in participants with time-averaged on-treatment DBP ≥82.9 mmHg (median) (vs. <82.9 mmHg; 17.3% vs. 14.1%; OR 1.25; 95% CI: 1.10–1.44). Furthermore, the lowest new-onset hyperuricemia risk (12.1%) was found in those with both time-averaged on-treatment SBP (median: 138.3 mmHg) and DBP below the median (P-interaction=0.023). The results were similar for time-averaged DBP during the first 12- or 24-month treatment period, or in the analysis using propensity scores. Furthermore, a non-significant higher risk of new-onset hyperuricemia was observed in participants with time-averaged on-treatment SBP ≥120 mmHg (vs. <120 mmHg; OR 1.61; 95% CI: 0.88–2.97). CONCLUSIONS: A tight DBP control of <82.9 mmHg was associated with lower risk of new-onset hyperuricemia among hypertensive patients without hyperuricemia.
format Online
Article
Text
id pubmed-7723605
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-77236052020-12-10 Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients Li, Qinqin Zhang, Yuanyuan Cao, Jingjing Zhang, Jingping Nie, Jing Liang, Min Li, Jianping Zhang, Yan Wang, Binyan Huo, Yong Wang, Xiaobin Hou, Fan Fan Xu, Xiping Qin, Xianhui Ann Transl Med Original Article BACKGROUND: The relationship between blood pressure (BP) control and the risk of new-onset hyperuricemia remains uncertain. We aimed to examine the association between degree of time-averaged on-treatment BP control and new-onset hyperuricemia in general hypertensive patients. METHODS: A total of 10,617 hypertensive patients with normal uric acid (UA) concentrations (<357 µmol/L) at baseline were included from the UA Sub-study of the China Stroke Primary Prevention Trial (CSPPT). Participants were randomized to receive a double-blind daily treatment of enalapril 10 mg and folic acid 0.8 mg or enalapril 10 mg alone. BP measurements were taken every three months after randomization. The primary outcome was new-onset hyperuricemia, defined as a UA concentration ≥417 µmol/L in men or ≥357 µmol/L in women at the exit visit. RESULTS: Over a median of 4.4 years, 1,664 (15.7%) participants developed new-onset hyperuricemia. Overall, there was a significantly positive association between time-averaged on-treatment diastolic BP (DBP) and new-onset hyperuricemia (per 10 mmHg increment; OR 1.13; 95% CI: 1.02–1.26). Consistently, a significantly higher risk of new-onset hyperuricemia was found in participants with time-averaged on-treatment DBP ≥82.9 mmHg (median) (vs. <82.9 mmHg; 17.3% vs. 14.1%; OR 1.25; 95% CI: 1.10–1.44). Furthermore, the lowest new-onset hyperuricemia risk (12.1%) was found in those with both time-averaged on-treatment SBP (median: 138.3 mmHg) and DBP below the median (P-interaction=0.023). The results were similar for time-averaged DBP during the first 12- or 24-month treatment period, or in the analysis using propensity scores. Furthermore, a non-significant higher risk of new-onset hyperuricemia was observed in participants with time-averaged on-treatment SBP ≥120 mmHg (vs. <120 mmHg; OR 1.61; 95% CI: 0.88–2.97). CONCLUSIONS: A tight DBP control of <82.9 mmHg was associated with lower risk of new-onset hyperuricemia among hypertensive patients without hyperuricemia. AME Publishing Company 2020-11 /pmc/articles/PMC7723605/ /pubmed/33313179 http://dx.doi.org/10.21037/atm-20-3017 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Li, Qinqin
Zhang, Yuanyuan
Cao, Jingjing
Zhang, Jingping
Nie, Jing
Liang, Min
Li, Jianping
Zhang, Yan
Wang, Binyan
Huo, Yong
Wang, Xiaobin
Hou, Fan Fan
Xu, Xiping
Qin, Xianhui
Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients
title Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients
title_full Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients
title_fullStr Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients
title_full_unstemmed Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients
title_short Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients
title_sort degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723605/
https://www.ncbi.nlm.nih.gov/pubmed/33313179
http://dx.doi.org/10.21037/atm-20-3017
work_keys_str_mv AT liqinqin degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT zhangyuanyuan degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT caojingjing degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT zhangjingping degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT niejing degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT liangmin degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT lijianping degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT zhangyan degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT wangbinyan degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT huoyong degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT wangxiaobin degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT houfanfan degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT xuxiping degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients
AT qinxianhui degreeofbloodpressurecontrolandtheriskofnewonsethyperuricemiaintreatedhypertensivepatients